144 related articles for article (PubMed ID: 30696815)
1. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.
Kriegsmann K; Baertsch MA; Awwad MHS; Merz M; Hose D; Seckinger A; Jauch A; Becker N; Benner A; Raab MS; Hillengass J; Bertsch U; Dürig J; Salwender HJ; Hänel M; Fenk R; Munder M; Weisel K; Müller-Tidow C; Goldschmidt H; Hundemer M
Blood Cancer J; 2019 Jan; 9(2):13. PubMed ID: 30696815
[TBL] [Abstract][Full Text] [Related]
2. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
3. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
4. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
5. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
[TBL] [Abstract][Full Text] [Related]
6. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
7. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
8. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
10. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
11. Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.
Cai QQ; Gao XM; Le J; Zhao H; Cai H; Cao XX; Li J
Ann Hematol; 2021 Jun; 100(6):1547-1552. PubMed ID: 33839882
[TBL] [Abstract][Full Text] [Related]
12. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
Abdulkarim H; Zourob M; Siaj M
Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.
Awwad MHS; Kriegsmann K; Plaumann J; Benn M; Hillengass J; Raab MS; Bertsch U; Munder M; Weisel K; Salwender HJ; Hänel M; Fenk R; Dürig J; Müller-Tidow C; Goldschmidt H; Hundemer M
Oncoimmunology; 2018; 7(10):e1486356. PubMed ID: 30288348
[No Abstract] [Full Text] [Related]
14. Cereblon binding molecules in multiple myeloma.
Kortüm KM; Zhu YX; Shi CX; Jedlowski P; Stewart AK
Blood Rev; 2015 Sep; 29(5):329-34. PubMed ID: 25843596
[TBL] [Abstract][Full Text] [Related]
15. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
Misiewicz-Krzeminska I; Corchete LA; Rojas EA; Martínez-López J; García-Sanz R; Oriol A; Bladé J; Lahuerta JJ; Miguel JS; Mateos MV; Gutiérrez NC
Haematologica; 2018 May; 103(5):880-889. PubMed ID: 29545347
[TBL] [Abstract][Full Text] [Related]
16. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
17. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
18. Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.
Liu XP; He L; Zhang QP; Zeng XT; Liu SQ
Med Sci Monit; 2018 May; 24():2809-2817. PubMed ID: 29729093
[TBL] [Abstract][Full Text] [Related]
19. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
Tochigi T; Miyamoto T; Hatakeyama K; Sakoda T; Ishihara D; Irifune H; Shima T; Kato K; Maeda T; Ito T; Handa H; Akashi K; Kikushige Y
Blood; 2020 Jun; 135(24):2146-2158. PubMed ID: 32219443
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
